Exceptional growth for Venture Capital Deals in radiopharmaceutical companies in 2023

8 Dec 2023 | Misc, Radiopharmaceutical Therapy

GlobalData Reports that Venture Capital Deals in radiopharmaceutical companies have grown 550% to $408m in 2023 GlobalData reports that venture capital deals in radiopharmaceuticals have grown by 550% this year totalling $408m. It was only back in 2017 when the level...

Dr Lena Unterrainer presents data on [Ga-68]EMP-100 at EANM 2023

12 Sep 2023 | [Ga-68]EMP-100, Collaborations, Radiopharmaceutical Therapy

Dr Lena Unterrainer presented [Ga-68]EMP-100 as one of the “dark horses of theranostics” and showed the data of [Ga-68]EMP-100 in...

Results published by Investigator on non-invasive assessment of c-MET expression in non-small cell lung cancer

1 Mar 2023 | [Ga-68]EMP-100, Collaborations

A case of a 56-year-old female former smoker with stage IV EGFR mutation-positive NSCLC (lymphogenic, pulmonary, hepatic, and cerebral metastases is presented. Stage: cT3, cN3, cM1b) and concomitant MET exon 14 skipping mutation. After multiple pretreatments including...

Christophe Portal is Promoted to CSO for Edinburgh Molecular Imaging

1 Mar 2023 | Corporate

Dr Christophe Portal has been appointed as Chief Scientific Officer. Christophe has 15 years of industrial experience in the research and development of peptide and peptide like molecules for imaging and therapy. He started his career working for a biotechnology...

Alex Gibson is Promoted to CEO for Edinburgh Molecular Imaging

1 Mar 2023 | Corporate

Dr Alex Gibson has been appointed as Chief Executive Officer. Alex has over 25 years of experience in the radiopharmaceutical industry starting as a radiochemist with Amersham  (now part of GE Healthcare). Following several roles within imaging pharmaceutical R&D,...

Edinburgh Molecular Imaging Appoints New Chairman

1 Mar 2023 | Corporate, Events

Edinburgh Molecular Imaging appoints Dr Rob James as Non-Executive Chairman Rob is currently the Managing Partner of Sixth Element Capital and has over 20 years of experience of working in early-stage companies developing oncology drugs. He first worked at Cancer...

Results published by Investigator on identification and validation of MET as target for fluorescent guided surgery in papillary thyroid cancer

11 Apr 2022 | Collaborations, EMI-137

Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal...

Results published by Investigator on first-in-human biodistribution and first PET imaging results of [Ga-68]EMP-100 in metastatic renal cell carcinoma

6 Dec 2021 | [Ga-68]EMP-100, Collaborations

This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in metastases and primary RCC. Conclusion: Visualization of c-MET expression...

Results published by Investigator on Image-guided Surgery in Penile Squamous Cell Carcinoma Patients

21 May 2021 | Collaborations, EMI-137

This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient...

Results from Phase II clinical development of EMI-137 published

2 Oct 2020 | EMI-137

The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha 1-h...